All In Biotech

Drug Trial Radar · NCT01375920

Antiglucocorticoid Augmentation of antiDepressants in Depression

Last checked: Nov 20, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Feb 2011

Primary completion

Feb 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Jane BarnesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Health Research, United Kingdom
First posted
Jun 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Depression is one of the most common mental health problems, with at least one in six adults suffering from this at some time in their life. It can become long-lasting and frequently recurs. Depression has a large negative impact on quality of life of patients and their carers and it has also been shown to be one of the leading causes of working age adults receiving disability payments in the UK. The need for improved treatment has been recognised by the Department of Health and others. Improvements in drug treatments are therefore required. There has been recent increased understanding of some of the causes of the frequent lack of complete response seen with antidepressants. The stress hormone, cortisol, is often elevated or poorly controlled in depression and there is laboratory and clinical research to show that this hormonal change reduces the benefits from antidepressants with associated poor outcome and memory problems. Recently it has been shown in small studies that giving treatments that reduce cortisol or block its harmful effects for between 1 and 3 weeks overcome these negative consequences. Our group is particularly interested and experienced in this topic. The investigators plan to study a drug that decreases cortisol levels in people who have not recovered with standard antidepressants so that the investigators can find out the usefulness of this treatment (compared with placebo (dummy tablet)) in day to day life as well as checking closely for side-effects (the initial studies have shown that the particular drug the investigators wish to study (metyrapone) has few side effects). The investigators will also measure cortisol and see if its level can tell us which people do best with this treatment. The investigators will carry out this study in 3 centres across the UK. The investigators will carry out some additional tests of specific sorts of memory and decision making and also do this while scanning the brain (in a painless test). The results of these tests, along with tests of brain wave patterns, should help us understand more fully how this new treatment is working and who responds best to it. The study will help us find out if this drug should be used more widely for people not responding to standard treatments and will also lead on to the development of other new treatments with an anti-cortisol effect to help tackle the major problem of poor outcome from depression.

Conditions

  • Depression

Interventions

  • MetyraponeDrug

    500 milligrams to be taken twice a day orally

  • placeboDrug

    a matched placebo will be administered to patients to take twice a day for 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome will be the change in Montgomery-Asberg Depression Rating Scale (MADRS) from week 0 to +5 weeks.Time frame: 5 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Bradford District Care Trust

    Bradford, United Kingdom

  • Leeds Community Mental Health Team

    Leeds, United Kingdom

  • Affective Disorders Service

    Manchester, United Kingdom

  • Manchester Community Mental Health Team

    Manchester, United Kingdom

  • Manchester Magnetic Resonance Centre

    Manchester, United Kingdom

  • Northumberland, Tyne and Wear NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

  • Stockton Affective Disorders Service

    Newcastle upon Tyne, Teesside, United Kingdom

  • Newcastle Community Mental Health Team

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Regional Affective Disorders Service

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • North Tyneside Community Mental Health Team

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

  • Newcastle Magnetic Resonance Centre

    Newcastle upon Tyne, Tyne and Wear, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.